» Articles » PMID: 40041913

GSFM: A Genome-scale Functional Module Transformation to Represent Drug Efficacy for Drug Discovery

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2025 Mar 5
PMID 40041913
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacotranscriptomic profiles, which capture drug-induced changes in gene expression, offer vast potential for computational drug discovery and are widely used in modern medicine. However, current computational approaches neglected the associations within gene‒gene functional networks and unrevealed the systematic relationship between drug efficacy and the reversal effect. Here, we developed a new genome-scale functional module (GSFM) transformation framework to quantitatively evaluate drug efficacy for drug discovery. GSFM employs four biologically interpretable quantifiers: GSFM_Up, GSFM_Down, GSFM_ssGSEA, and GSFM_TF to comprehensively evaluate the multi-dimension activities of each functional module (FM) at gene-level, pathway-level, and transcriptional regulatory network-level. Through a data transformation strategy, GSFM effectively converts noisy and potentially unreliable gene expression data into a more dependable FM active matrix, significantly outperforming other methods in terms of both robustness and accuracy. Besides, we found a positive correlation between RS and drug efficacy, suggesting that RS could serve as representative measure of drug efficacy. Furthermore, we identified WYE-354, perhexiline, and NTNCB as candidate therapeutic agents for the treatment of breast-invasive carcinoma, lung adenocarcinoma, and castration-resistant prostate cancer, respectively. The results from and experiments have validated that all identified compounds exhibit potent anti-tumor effects, providing proof-of-concept for our computational approach.

References
1.
Shaker B, Ahmad S, Lee J, Jung C, Na D . In silico methods and tools for drug discovery. Comput Biol Med. 2021; 137:104851. DOI: 10.1016/j.compbiomed.2021.104851. View

2.
Jiramongkol Y, Lam E . FOXO transcription factor family in cancer and metastasis. Cancer Metastasis Rev. 2020; 39(3):681-709. PMC: 7497309. DOI: 10.1007/s10555-020-09883-w. View

3.
Ruiz de Porras V, Font A, Aytes A . Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett. 2021; 523:162-169. DOI: 10.1016/j.canlet.2021.08.033. View

4.
Yang C, Zhang H, Chen M, Wang S, Qian R, Zhang L . A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022; 11. PMC: 8893721. DOI: 10.7554/eLife.71880. View

5.
Bates S . The role of gene expression profiling in drug discovery. Curr Opin Pharmacol. 2011; 11(5):549-56. DOI: 10.1016/j.coph.2011.06.009. View